Replies to post #32208 on Revive Therapeutics Ltd (RVVTF)

[Gatorca]

Door wide open for Revive to dominate the general pop market.

This is potentially big news for $RVVTF. Pfizer just stopped their trial for standard risk patients for Paxlovid for COVID treatment. The data showed no improvement. Door wide open for Revive to dominate the general pop market. 💯@danfaraci @RexWiggins12 https://t.co/Jv5MM669PT

— The Dales Report (@TheDalesReport) June 14, 2022

Ps. could possibly add a little more to market cap

pps. or a Lot more....

ppps. probably last year working for many of us... hopefully just invest, trade even some, from home.